CASI CASI Pharmaceuticals Inc

USD 6.00 -0.35 -5.511811
Icon

CASI Pharmaceuticals Inc (CASI) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 6.00

-0.35 (-5.51)%

USD 0.09B

0.09M

USD 6.00(+0.00%)

N/A

Icon

CASI

CASI Pharmaceuticals Inc (USD)
COMMON STOCK | NSD
USD 6.00
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.09B

N/A

USD 6.00

CASI Pharmaceuticals Inc (CASI) Stock Forecast

Show ratings and price targets of :
USD 6.00
(+0.00%)

Based on the CASI Pharmaceuticals Inc stock forecast from 1 analysts, the average analyst target price for CASI Pharmaceuticals Inc is USD 6.00 over the next 12 months. CASI Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of CASI Pharmaceuticals Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, CASI Pharmaceuticals Inc’s stock price was USD 6.00. CASI Pharmaceuticals Inc’s stock price has changed by -4.00% over the past week, +63.93% over the past month and +145.90% over the last year.

No recent analyst target price found for CASI Pharmaceuticals Inc
No recent average analyst rating found for CASI Pharmaceuticals Inc

Company Overview CASI Pharmaceuticals Inc

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditi...Read More

1701-1702, China Central Office Tower 1, Beijing, China, 100025

176

December

USD

USA

Adjusted Closing Price for CASI Pharmaceuticals Inc (CASI)

Loading...

Unadjusted Closing Price for CASI Pharmaceuticals Inc (CASI)

Loading...

Share Trading Volume for CASI Pharmaceuticals Inc Shares

Loading...

Compare Performance of CASI Pharmaceuticals Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for CASI

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To CASI Pharmaceuticals Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +4.34 (+0.88%) USD126.85B 31.94 20.00

ETFs Containing CASI

Symbol Name CASI's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About CASI Pharmaceuticals Inc (CASI) Stock

Based on ratings from 1 analysts CASI Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on CASI's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for CASI is USD 6.00 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 6.

Unfortunately we do not have enough data on CASI's stock to indicate if its overvalued.

The last closing price of CASI's stock was USD 6.00.

The most recent market capitalization for CASI is USD 0.09B.

Based on targets from 1 analysts, the average taret price for CASI is projected at USD 6.00 over the next 12 months. This means that CASI's stock price may go up by +0.00% over the next 12 months.

We can't find any ETFs which contains CASI Pharmaceuticals Inc's stock.

As per our most recent records CASI Pharmaceuticals Inc has 176 Employees.

CASI Pharmaceuticals Inc's registered address is 1701-1702, China Central Office Tower 1, Beijing, China, 100025. You can get more information about it from CASI Pharmaceuticals Inc's website at https://www.casipharmaceuticals.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...